근감소증, 표적항암제, BCR-ABL, T315I, RET, FGFR4, KIT, CSF1R, sarcopenia, targeted cancer agents
Investors 5
Mentions in press and media 5
| Date | Title | Description |
| 12.03.2026 | ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026 | Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform
Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804
SEOUL, South Korea, March 12, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., ... |
| 13.02.2026 | Q2 INTERIM REPORT OCT – DEC 2025 | Q2 INTERIM REPORT OCT – DEC 2025
Fri, Feb 13, 2026 09:00 CET Report this content OPENING REMARKS
Hamlet BioPharma is identified as a mature pharmaceutical company, having reached major milestones, based on achievements of individual project... |
| 03.02.2026 | Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea | Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea
Tue, Feb 03, 2026 10:15 CET Report this content
Hamlet BioPharma has signed an agreement with the Korean biotech company ImmunoForge, to develop novel administr... |
| 14.01.2025 | ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND ... | SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment for DMD (Duchenne Muscular Dystrophy) c... |
| 29.10.2021 | ImmunoForge Inc. receives U.S. FDA ODD for PF1801 | SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOs Sung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug cand... |
Reviews 0
